Presentation given by Manel Cascallo, from VCN Biosciences, in the framework of the Emergence Forum Barcelona
Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014
An overview the IPL’s website, anatomy of an IPL reference response, and statistics gathered from 2007 data about reference service and digital collections usage.
An overview the IPL’s website, anatomy of an IPL reference response, and statistics gathered from 2007 data about reference service and digital collections usage.
Presentation given by Eugenio Hack from Mediterranean Life Pharma SL in the framework of the Emergence Forum Barcelona
Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014
Presentation given by Céline Thizon from BiotechDeva in the framework of the Emergence Forum Barcelona
Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014
Presentation given by Jean-Pierre Saintouil from Toulouse Tech Transfer in the framework of the Emergence Forum Barcelona
Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014
Creativity in the language classroom with Animotomickstout
For EFL instructors looking to help their learners engage with English in creative ways, Internet-based applications offer numerous exciting possibilities to provide learners with authentic reasons for using English. This presentation introduces Animoto, an easy to use web-based application ideal for creating professional looking short videos and demonstrates its efficacy in two different EFL learning contexts.
Presentation given by Philippe Baralon from Scanelis in the framework of the Emergence Forum Barcelona
Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014
Presentation given by Alain-Michel Boudet from University of Toulouse III, Paul Sabatier in the framework of the Emergence Forum Barcelona
Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014
Presentation given by Eugenio Hack from Mediterranean Life Pharma SL in the framework of the Emergence Forum Barcelona
Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014
Presentation given by Céline Thizon from BiotechDeva in the framework of the Emergence Forum Barcelona
Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014
Presentation given by Jean-Pierre Saintouil from Toulouse Tech Transfer in the framework of the Emergence Forum Barcelona
Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014
Creativity in the language classroom with Animotomickstout
For EFL instructors looking to help their learners engage with English in creative ways, Internet-based applications offer numerous exciting possibilities to provide learners with authentic reasons for using English. This presentation introduces Animoto, an easy to use web-based application ideal for creating professional looking short videos and demonstrates its efficacy in two different EFL learning contexts.
Presentation given by Philippe Baralon from Scanelis in the framework of the Emergence Forum Barcelona
Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014
Presentation given by Alain-Michel Boudet from University of Toulouse III, Paul Sabatier in the framework of the Emergence Forum Barcelona
Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014
Global breast cancer vaccine clinical trial insightKuicK Research
“Global Breast Cancer Vaccine Clinical Trial Insight” Report Highlight:
Global Breast Cancer Vaccine Market Overview
Global Breast Cancer Vaccine Clinical Pipeline by Company, Phase & Country
Mechanism of Breast Cancer Vaccine & Personalized Cancer Vaccines
Detailed Clinical Insight on Breast Cancer Vaccine Pipeline: 35 Vaccines
Majority in PHASE-I Clinical Trial: 12 Vaccines
Highest Clinical Phase is PHASE-III: 2 Vaccines (NeuVax & OBI-822)
Manipal Hospital is the best multispeciality hospital in Jayanagar Bangalore near JP Nagar, Banashankari which provides top-notch medical & healthcare services.Visit us at: https://www.manipalhospitals.com/jayanagar/
Global breast cancer monoclonal antibodies market outlook 2020 1KuicK Research
" Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" Report Highlights:
Breast Cancer Monoclonal Antibodies Mechanism
Global Breast Cancer Monoclonal Antibody Market Analysis
Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
Marketed Breast Cancer Monoclonal Antibodies: 6 mAb
Global cancer vaccine market & clinical trial insightKuicK Research
“Global Cancer Vaccine Market & Clinical Trial Insight” Report Highlights:
Global Cancer Market Overview
Emergence of Personalized Cancer Vaccines
Platforms for Cancer Vaccines Delivery
Mechanism of Cancer Vaccines
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 298 Vaccines
Marketed Cancer Vaccines: 15 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing
Global breast cancer monoclonal antibodies market outlook 2020KuicK Research
" Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" Report Highlights:
Breast Cancer Monoclonal Antibodies Mechanism
Global Breast Cancer Monoclonal Antibody Market Analysis
Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
Marketed Breast Cancer Monoclonal Antibodies: 6 mAb
Download Global breast cancer monoclonal antibodies market outlook 2020KuicK Research
\" Global Breast Cancer Monoclonal Antibodies Market Outlook 2020\" Report Highlights:
Breast Cancer Monoclonal Antibodies Mechanism
Global Breast Cancer Monoclonal Antibody Market Analysis
Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
Marketed Breast Cancer Monoclonal Antibodies: 6 mAb
Oncolytic Virus Therapy Development - Creative BiolabsCreative-Biolabs
Oncolytic virotherapy is cancer treatment using a native or reprogrammed virus that has the potential to targeting and killing cancerous cell. Taking advantage of the OncoVirapy™ platform, Creative Biolabs provides customized, standardized, and reliable and high-quality oncolytic virus therapy development services for clients globally.
2016 11-17 Oncology by design 2016 course, Amsterdam, Alain van GoolAlain van Gool
Lecture on the the role of biomarkers in oncology drug development, given to a group of pharmaceutical industry specialists, in tandem with a lecture on oncology companion diagnostics given by Martina Kaufmann.
Cell & Gene Therapy Preclinical Development SolutionsCovance
Cell & Gene Therapy preclinical development solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
Biocat is the institution that brings together the life sciences and healthcare innovation community in Catalonia.
Created in 2006 at the behest of the Government of Catalonia, Biocat’s mission is to maximize the economic and social impact of the life sciences and healthcare innovation of the BioRegion.
Biocat focuses its strategy on different key points:
- Raising awareness and promoting the ecosystem, creating tools and strategies for improving the knowledge of the Catalan healthcare sector and increasing its projection both at home and abroad, with the aim of positioning the BioRegion as an international reference.
- Providing innovative training and developing talent, by designing and executing programs and initiatives to improve talent and entrepreneurship considered essential factors for the growth of the sector.
- Accelerating technology transfer and business growth by supporting and carrying out activities for increasing the value of the sector, placing special emphasis on the added value of research, knowledge and technology transfer, internationalization and access to capital.
The BioRegion is the healthcare and life sciences ecosystem in Catalonia, meaning the group of companies, research groups and bodies, hospitals, universities, administrations, researchers and entrepreneurs, innovation and knowledge-transfer support structures working in Catalonia in this strategic sector.
With a population of more than 7.5 millions and territory comparable to that of European countries like Belgium or the Netherlands, Catalonia has the most dynamic life sciences ecosystem in Spain and one of the most active in Europe. Biocat is the body responsible for dynamizing and promoting the BioRegion of Catalonia.
Biocat has experience in accelerating healthcare projects and developing talent since 2008. In 10 years, Biocat has invested over €11 million, distributed in 300 programs attended by more than 2,300 students. By leveraging its expert, industry experienced, staff and extended network, Biocat has successfully accelerated 96 life sciences projects that generated 300 new job positions, increased the rate of successful commercialization and reduced the time to next phase. In 2013, in order to increase the impact of these strategic activities. Biocat launched Moebio, a new initiative that brings together diferent training programs to accelerate entrepreneurship and innovation in healthcare, that counts with the support of EIT Health. Moebio is ranked as one of the top accelerators in Europe according to rankings by Digitalhealth.careers, Mobile World Capital, Tech EU and HealthStartup.
Design Health Barcelona (d·HEALTH Barcelona) is a 9-month postgraduate program to develop entrepreneurs and future leaders in healthcare innovation. The course, based on the prestigious Stanford University's Biodesign Fellowship, has a needs-driven innovation focus and it guides multidisciplinary groups of students through a full cycle of innovation, from needs identification to designing and prototyping a viable solution, as well as searching for funding.
www.moebio.org
Keynote conference during the Biocat Report 2017, by Dr. Daria Tataj, Founder of a strategy firm Tataj Innovation, and Chairwoman of the RISE High-Level Advisors to Carlos Moedas, European Commissioner for Research, Science and Innovation
Panel discussion: Being a successful healthcare entrepreneur: lessons from Boston to Barcelona, with numerous experts from CIMIT, Boston, in economics, development and strategic planning of medical devices; in prototypes and patents and founders of several startups.
Presentation of CRAASH Barcelona, the new project of Biocat (Moebio Barcelona). The initiative is a 12-week program that helps European research teams launch successful device, diagnostic and e-/digital health innovations to improve health and patient care.
Toby Reid, Managing Director at BioCity Scotland, was the keynote speaker of the Graduation Cerimony of d·HEALTH Barcelona 2017.
BioCity is UK's largest bioscience incubation centre. Over 200 companies are based in a BioCity Group business incubator, with a 91% survival rate of companies.
Moebio is he talent development initiative of Biocat to accelerate healthcare entrepreneurship.
Design Health Barcelona (d·HEALTH Barcelona) Is the full-time program of MOEBIO, inspired and modeled in the prestigiousStanford University's Biodesign Fellowshipthat seeks to train a team of fellows in the process of biodesign to develop innovative solutions.
Presentation of Mehrdad Hariri (Canadian Science Policy Centre (CPSC), CEO & President) at the Forum of the BioRegion of Catalonia, organized by Biocat.
Presentation of Zayna Khayat (MaRS Discovery District, Health System Innovation; MaRS EXCITE) at the Forum of the BioRegion of Catalonia, organized by Biocat.
Presentation of Susan Bannister (Massachusetts Life Sciences Center, Former President and CEO) at the Forum of the BioRegion of Catalonia, organized by Biocat.
Presentation of Vishal Gulati (Draper Esprit, Venture Partner; Horizon Discovery Group PLC, Board Director) at the Forum of the BioRegion of Catalonia, organized by Biocat.
Presentation of Simon Howell (Founding Non-Executive Director of MedCity and Guy’s Campus Dean at King’s College London King’s College London) at the Forum of the BioRegion of Catalonia, organized by Biocat.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
3. www.vcnbiosciences.com
The origin
normal cell:
abortive replication
Productive
replication
Mechanism of Action
Spread to neighbouring cells
Selective killing of
tumour cells
Self-amplification effect
Potential stimulation of
an antitumoral immune
response
Oncolytic Virotherapy =
Use of replication competent viruses to
selectively destroy cancer cells
Technology
(Extracted from Hedley et al. 2006)
4. www.vcnbiosciences.com
Genesis of VCN Biosciences
Virotherapy Group at ICO / IDIBELL experience
2001 2002 2003 20072004 2005 2006 2008 2009 2010
1rst patent
(VA technology)
2nd patent
(DM technology)
3rd patent
(T1 tech.)
Technology Acquisition
by ORCA Therapeutics
(Holland)
EUREKA project
VCN creation
Regulatory Phase
with ICOVIR-5
Approval by:
- AEMPS
- Environmental Ministry
- Clinical committee at
Hospitals
4th patent
(hyal. tech.)
Technology Transfer to
DNAtrix (USA)
Compassionate Use
Assays ICOVIR-5
Technology Acquisition
by Oncolytics BioTech
(Canada)
CONTRACT RESEARCH
with Oncolytics BioTech.
5. www.vcnbiosciences.com
Dr. Ramon Alemany Dr. Manel CascallóDr. Gabriel Capellà
Internationally Recognized Scientifics
Expertise in Clinical Development of Oncolytic viruses
Inventors of >5 patents & Company Consultants
Business Management Expertise
ENTERPRENEUR TEAM
adhoc Scientific Advisory Board
Dr. Jose Costa (Yale Univ., USA)
Dr. Nick Lemoine (QMCR, UK)
Dr. Ramon Salazar (ICO, Spain)
Dr. Manuel Hidalgo (CNIO, Spain)
Strategic Consultancy
BIOEMPREN SL
(Mr. Jaume Amat)
Hyaluronidase Tech. Transfer
IDIBELL / ICO
Commercial agreement with
a CMO for viral batch production
GenIBET
(Portugal)
Genesis of VCN Biosciences
The decision
6. About VCN Biosciences
Mission & View
www.vcnbiosciences.com
VCN Biosciences was created in 2009 with the aim of developing new agents for the treatment of cancer using a
technological platform based on oncolytic adenoviruses.
VCN Biosciences mission is the development of new candidate oncolytic adenoviruses from its design and
preclinical studies to the validation of their antitumoural efficacy in human patients (Phase I and II clinical trials).
7. www.vcnbiosciences.com
Rational Design of a Clinical candidate
HAd5
(wild-type)
Clinical candidate
selectivity of replication
in tumour cells
Tumour potency
(diffusion)
biodistribution selectivity
(tumour targeting)
Mechanism of Action
Selective killing of tumor cells by effect of its
replication, which results in a self-
amplification of the initial inoculum that is
released after cell lysis and spread through
the tumor mass
The expression of a secreted soluble
hyaluronidase, which degrades partially the
extracellular matrix of the tumor facilitating the
diffusion of the virus progeny and increasing
the accessibility for chemotherapy
About VCN Biosciences
12. Building up VCN Biosciences
www.vcnbiosciences.com
1.- Biodistribution
Liver
PBS Wild-type
capsid
RGDK
capsid
1,00E+04
1,00E+05
1,00E+06
1,00E+07
1,00E+08
1,00E+09
1,00E+10
0 500 1000 1500 2000
Virusinblood
Time (minutes)
ICO17
VCN01
2.- Pharmacokinetics
Orphan Drug Designation for the
Treatment of Pancreatic Cancer
Decision adopted by EMA
on June 21th, 2011
(EU/3/11/880 - EMA/OD/008/11)
Days post-injection
%tumorgrowthvsday0
VCN-01
%tumorgrowthvsday0
VCN-01
3.- Antitumoral ACTIVITY
13. Building up VCN Biosciences
www.vcnbiosciences.com
Preclinical Package: Pharmacology of VCN-01
Intratumoral
Administration
*p<0.05 vs PBS
# p<0.05 vs VCN-01 (4xE9vp)
0
500
1000
1500
2000
2500
-1 19 39 59 79
Volume(mm3)
day pi
Tumor volume NP-9
(Mean ± S.E.)
PBS
VCN01
Hyaluronic Acid (HA)
staining
Digested HA
(neg. ctrl)
vehicle
VCN01
(day79 p.i.)
hyaluronic acid hyaluronic acid
Intravenous
Administration
*, p<0.05 vs vehicle group
14. Building up VCN Biosciences
www.vcnbiosciences.com
Preclinical Package: Pharmacology of VCN-01 ± Gemcitabine
day 0 day 80
nude
MICE
day -15
Tumor cells
- VCN-01 i.v. at 5.1010 vp (1X): day 0
- GE i.p. at 100 mg/kg (3X): day 0,2,4,6
Human xenograft model
in mice
Syngenic Model in Syrian
Hamster
day 0 day 45
Syrian
Hamster
day -15
Tumor cells
GE i.p. at 50 mg/kg (7X): day 0,3,6,9,12,15,18)
VCN-01 i.t. at 25.1010 vp (1X): day 0, 9 & 18)
# P<0.01 vs GE
ᵟP<0.01 vs VCN-01
P<0.01 vs PBS
*
15. Building up VCN Biosciences
www.vcnbiosciences.com
Preclinical Package: Toxicity profile
* p<0.05 vs PBS
Transaminases
1
10
100
1000
10000
100000
male female male female
UI/l
Day 2
1
10
100
1000
10000
100000
male female male female
UI/l
Day 8
vehicle
VCN-01 at 2,5E11 vp
VCN-01 at 4E11 vp
1
10
100
1000
10000
100000
male female male female
UI/l
Day 28
AST ALT AST ALT AST ALT
*p <0.05 vs vehicle group
*
*
Total white blood cells count
0,001
0,01
0,1
1
10
100
male female male female male female male female male female
x10E6cells/mL
Day 2
0,001
0,01
0,1
1
10
100
male female male female male female male female male female
x10E6cells/mL
Day 8
vehicl
VCN-0
VCN-0
Lymphocytes Neutrophils Eosinophils Basophils Monocytes
Lymphocytes Neutrophils Eosinophils Basophils Monocytes
*
*
*
*
1
10
100
1000
10000
100000
male female male female
UI/l
Day 8
vehicle
VCN-01 at 2,5E11 vp
VCN-01 at 4E11 vp
*p <0.05 vs vehicle group
Mice
Hamster
Day 12Day 7
16. Building up VCN Biosciences
www.vcnbiosciences.com
MANAGEMENT INVESTMENT
BUDGET STRUCTURE
ACTIVITY SCHEDULING
FINANCIAL OPPORTUNITIES
FFF
entrance
Manel Cascalló (59,13 %)
Ramon Alemany (7,39%)
Gabriel Capellà (7,39%)
BIOVCN Patrimonial (13,66 %)
BIOCAPE Grup (12,43 %)
Founders: 100%
Manel Cascalló (35,5 %)
Ramon Alemany (4,4%)
Gabriel Capellà (4,4 %)
BIOVCN Patrimonial (8,2 %)
BIOCAPE Grup (7,5 %)
New Investor (40%)
Second Round Grifols
(expected)
Manel Cascalló (35,5 %)
Ramon Alemany (4,4%)
Gabriel Capellà (4,4 %)
BIOVCN Patrimonial (8,2 %)
BIOCAPE Grup (7,5 %)
New Investor (40%)
COMPANYVALUE
Manel Cascalló (35,5 %)
Ramon Alemany (4,4%)
Gabriel Capellà (4,4 %)
BIOVCN Patrimonial (8,2 %)
BIOCAPE Grup (7,5 %)
New Investor (40%)
17. Building up VCN Biosciences
www.vcnbiosciences.com
MANAGEMENT
ORGANIZATION
TRAINING
& CONSULTING
FUNDING
SEARCH
GROWTH
STRATEGY
Founder Team
Dr. Alemany
Virotherapy Expert
Dr . Capellà
Cancer Genetics
Expert
Contract Research
with academia
Scientific Advisory Committe
Dr. Hidalgo
CNIO
Dr. Salazar
ICO
Dr. Costa
Yale Univ.
Dr. Cascallo,
CEO / Founder
Ms. Viaplana
Clinical Research
Manager
Ms. Blasi
Regulatory
Affairs
Manager
Dr. Bazan
R&D Manager
Clinical
Commitee
Scientists
Team
Board of Directors
Dr. Terencio Dr. Büscher Dr. Costa Mr. AmatDr. Cascalló
18. www.vcnbiosciences.com
VCN Biosciences Pipeline
Proof of
concept
Phase II
Candidate
definition
Phase I
Regulatory
Preclínics
Hyaluronidase
Technology
VCN-01
T1- Technology
Out-licensed to
ORCATherapeutics BV
VCN-02
Technology
VCN-02
Pre-candidates
VCN Technologies
Building up VCN Biosciences
19. www.vcnbiosciences.com
Clinical program with VCN-01
Phase I by Intravenous
Administration ±GE
(EudraCT number: 2012-005555-16 )
Phase I by Intratumoral
Administration ±GE
(EudraCT number: 2012-005556-42 )
Study Type Open-label / Dose Escalation Open-label / Dose Escalation
Dosage Range 1xE11 vp to 1xE13 vp/patient
(6 dose levels)
1xE10 vp to 1xE12 vp/tumor
(5 dose levels)
Administration Continuous infusion EUS guided
Number of patients 24 to 33 20 to 27
Clinical Sites 1. Institut Català d’Oncologia
(BCN)
2. Centro Integral Oncológico Clara
Campal (Madrid)
1. Institut Català d’Oncologia
(BCN) / Hospital Bellvitge
2.Centro Integral Oncológico
Clara Campal (Madrid)
Starting Date January 2014 January 2014
Estimative Duration Enrollment 24 months 19 months
Building up VCN Biosciences
20. Thank you!
www.vcnbiosciences.com
Dr. Manel Cascalló
Chief Executive Officer
VCN Biosciences SL
www.vcnbiosciences.com
Av de la Generalitat 152
08174 - Sant Cugat del Vallès (Barcelona, SPAIN)
phone: +34 571 2359 / + 34 609432375
mcascallo@vcnbiosciences.com
Funding:
- NEBT2010 - ACC10
- Programa INNPACTO-2012
- CDTI – PiD 2013